Prediction of dissolution-absorption relationships from a continuous dissolution/Caco-2 system
- 385 Downloads
The objectives were 1) to design a continuous dissolution Caco-2 system to predict the dissolution-absorption relationships for fast and slow dissolving formulations of piroxicam, metoprolol tartrate, and ranitidine HCl, and compare the predicted relationships with observed relationships from clinical studies; 2) to estimate the effect of croscarmellose sodium on ranitidine dissolution-absorption relationships; and 3) to estimate the effect of solubilizing agents on piroxicam dissolution-absorption relationships. A continuous dissolution/Caco-2 system was constructed from a dissolution apparatus and a diffusion cell, such that drug dissolution and permeation across a Caco-2 monolayer would occur sequentially and simultaneously. The continuous system generally matched observed dissolution-absorption relationships from clinical studies. For example, the system successfully predicted the slow metoprolol and slow ranitidiine formulations to be permeation-rate-limited. The system predicted the slow piroxicam formulation to be dissolution-rate-limited, and the fast piroxicam formulation to be permeation-rate-limited, in spite of piroxicam’s high permeability and low solubility. Additionally, the system indicated croscarmellose sodium enhanced ranitidine permeability and predicted solubilizing agents to not modulate permeability. These results suggest a dissolution/Caco-2 system to be an experimentally based tool that may predict dissolution-absorption relationships from oral solid dosage forms, and hence the relative contributions of dissolution and permeation to oral drug absorption kinetics.
KeywordsRanitidine Piroxicam Continuous System Sodium Lauryl Sulfate Solubilizing Agent
- 4.Goskonda S, Propst C, Augsburger LL, Schwartz P, Lesko LJ. Investigating the influence of formulation and process variables on the performance of ranitidine HCl tablets. Pharm Res. 1994;11:S-163.Google Scholar
- 5.Piscitelli DA, McGlone Dalby J, Augsburger LL, Shah VP, Lesko LJ, Young D. The effect of formulation (FM), process (P) and batch size (BS) on the oral bioavailability of ranitidine (R) tablets. Pharm Res 1995;12:S-417.Google Scholar
- 6.United States Pharmacopeia XXIII. Rockville, MD: US Pharmacopeial Convention. 1994.Google Scholar
- 20.Corrigan OI, Stanley CT. Dissolution properties of phenobarbitone-β-cyclodextrin systems. Pharm Acta Helv. 1981;56:204–208.Google Scholar